Keith T. Flaherty, M.D. is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma described in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first or senior author. He is the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors in 2019. He serves as editor-in-chief of Clinical Cancer Research. Dr. Flaherty co-founded Loxo Oncology in 2013 and served on the board of directors through the acquisition by Eli Lilly in 2019. He co-founded X4 Pharmaceuticals (NASDAQ: XFOR) and privately held Strata Oncology (2015), Apricity Oncology (2017), C-Reveal (2020), and most recently, Scorpion Therapeutics (2020). He serves on the boards of directors for Clovis Oncology, Checkmate Pharmaceuticals and Kinnate BioPharma.